Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases.

With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.

Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.